Is RKLB Overvalued or Undervalued Based on Stock Price Statistics and Investment Thesis

Based on the stock price statistics, RKLB's current valuation is a topic of debate. The company's market capitalization is around $100 million, which is relatively small compared to its industry peers.

The stock price has been steadily increasing over the past year, with a growth rate of 20%. This has led some investors to believe that RKLB is overvalued, as its price-to-earnings ratio is higher than its industry average.

However, the company's investment thesis suggests that it has a strong growth potential due to its innovative technology and expanding market reach. According to the company's financial reports, its revenue has been increasing by 15% annually over the past three years.

RKLB's management team has a proven track record of delivering results, with a 10-year experience in the industry. Their expertise and vision are key factors that contribute to the company's growth potential.

Rocket Lab's valuation raises some red flags. The forward price-to-sales (P/S) ratio is 16.77x, which is 20x higher than the aerospace industry's average of 0.83x.

The company's intrinsic value under the Base Case scenario is $6.81 USD, indicating it's overvalued by 85% compared to its current market price of $46.26 USD.

We can see this discrepancy in the Valuation Ratios section, which shows that Rocket Lab's PE Ratio and Forward PE are both listed as "n/a" or not available.

Rocket Lab's valuation is a topic of interest, with a market cap of $22.39 billion and an enterprise value of $22.14 billion.

The company's valuation ratios are also noteworthy, with a price-to-sales (P/S) ratio of 46.33, which is significantly higher than the aerospace industry's average of 0.83x.

Rocket Lab's enterprise valuation is also quite high, with an EV/Sales ratio of 43.90, indicating that investors are willing to pay a premium for the company's growth prospects.

However, some analysts have raised concerns about the company's valuation, citing its high P/S ratio and lack of profitability. In Q1, adjusted EBITDA stayed negative at $30 million, with R&D and SG&A costs climbing as the company invests in Neutron.

Despite these concerns, some analysts are optimistic about Rocket Lab's growth prospects, with a forward price target of $46.62 USD.

Here's a summary of Rocket Lab's valuation metrics:

Overall, Rocket Lab's valuation is a complex issue, with both optimistic and pessimistic views on the company's growth prospects and valuation multiples.

Rocket Lab's financial efficiency is a concerning area, with a return on equity (ROE) of -40.45% and return on invested capital (ROIC) of -13.13%. This means the company is actually losing money on its investments.

Rocket Lab's revenue per employee is a healthy $240,125, but its profits per employee are a staggering -$110,150. This suggests that the company is struggling to turn its revenue into actual profits.

The company's asset turnover is a relatively low 0.37, indicating that Rocket Lab is not generating enough revenue from its assets. This is a red flag for investors, as it suggests that the company's assets are not being used effectively.

Rocket Lab's employee count is 2,100, and its inventory turnover is a moderate 3.05. While this is not necessarily a cause for concern, it's worth noting that the company's financial efficiency is still a major issue.

Here's a summary of Rocket Lab's financial efficiency metrics:

Rocket Lab's financial performance is a mixed bag. The company has a current ratio of 2.67, indicating that it has sufficient liquidity to meet its short-term obligations. However, its debt-to-equity ratio of 0.72 suggests that it may be taking on too much debt.

Rocket Lab's revenue has been growing, reaching $504.26 million in the last 12 months. However, its losses have also been substantial, totaling -$231.31 million. The company's loss per share was -$0.46.

Here are some key financial metrics for Rocket Lab:

Rocket Lab's profitability score is 24/100, indicating that it is not very profitable. Its adjusted EBITDA was negative $30 million in Q1, and its R&D and SG&A costs are climbing as the company invests in new projects.

Rocket Lab's financial performance has been a mixed bag. The company had revenue of $504.26 million in the last 12 months, but also reported a net loss of $231.31 million. The loss per share was -$0.46.

The company's gross margin is 29.04%, but its operating and profit margins are negative, at -44.08% and -45.87% respectively. This suggests that Rocket Lab is struggling to turn a profit from its operations.

Here's a breakdown of Rocket Lab's income statement:

Rocket Lab's balance sheet shows that it has $688.14 million in cash and $498.14 million in debt, giving it a net cash position of $251.16 million or $0.52 per share. The company's current ratio is 2.67, indicating that it has sufficient liquidity to meet its short-term obligations.

However, Rocket Lab's profitability score is only 24/100, indicating that it is not very profitable. Its solvency score is 58/100, suggesting that it has some solvency issues. The company's return on equity (ROE) is -40.45%, and its return on invested capital (ROIC) is -13.13%. These metrics suggest that Rocket Lab is not generating enough returns on its equity and invested capital.

The company's financial performance is a key indicator of its overall health. The current ratio is 2.67, which suggests that the company has a strong ability to pay its short-term debts.

The debt-to-equity ratio is 0.72, indicating that the company's debt is relatively low compared to its equity. This is a good sign, as it suggests that the company is not over-leveraging itself.

Rocket Lab does not appear to pay any dividends at this time, which means that shareholders are not receiving any cash returns on their investment. The dividend yield is not applicable (n/a).

However, the company does have a buyback yield of -3.32%, which means that it is currently buying back its own shares. This can be a sign that the company is confident in its future prospects and wants to return value to its shareholders.

Here's a breakdown of the company's shareholder yield:

Overall, the company's financial performance is a mixed bag. While it has a strong current ratio and low debt-to-equity ratio, it is not paying any dividends and has a negative shareholder yield.

The average price target for Rocket Lab is $38.50, which is -16.77% lower than the current price.

Analysts project revenue to grow to $1.2 billion by 2027, with a revenue growth forecast of 32.54% over the next 5 years.

The consensus rating is "Buy", with 13 analysts providing recommendations.

Here's a breakdown of the analyst recommendations:

The average brokerage recommendation (ABR) is 1.87, with a low ABR of 1.87 and a high ABR of 1.93 over the past month.

The current ABR is based on 15 recommendations from brokerage firms, with 8 of those recommendations being Strong Buy.

Delayed NSDQ Data can be a challenge to navigate, but understanding the basics can help. The stock price for NSDQ is currently at $60.72, a 0.26% increase after-market.

This stock's performance is tracked by Zacks, a reputable source for financial analysis. According to Zacks, the stock has a Zacks Rank of 3, indicating a Hold rating. This means the stock is expected to perform at the same level as the market average over the next 1 to 3 months.

The Zacks Rank system is a powerful tool for investors, providing a clear indication of a stock's potential. Here's a breakdown of the Zacks Rank system:

The Momentum Scorecard also provides valuable insights into a stock's performance. It focuses on price and earnings momentum, helping investors identify the right time to enter a stock.

Rocket Lab USA Inc's financial health is a mixed bag. The company has a current ratio of 2.67, indicating it can cover its short-term debt, but its debt-to-equity ratio of 0.72 suggests a relatively high level of debt.

The company's profitability is a concern, with a return on equity (ROE) of -40.45% and return on invested capital (ROIC) of -13.13%. This means that for every dollar invested, the company is actually losing more than that amount.

Here's a breakdown of Rocket Lab's financial health:

The RKLB Solvency Score is a crucial indicator of a company's financial health. It measures how well a company can meet its financial obligations, and it's calculated based on various financial ratios.

Rocket Lab USA Inc's solvency score is 58/100. This score indicates that the company has some solvency issues, but it's not in a critical state.

To better understand Rocket Lab's solvency situation, let's take a look at its current financial position. The company has a current ratio of 2.67, which means it has sufficient liquid assets to cover its short-term debts. However, its quick ratio of 2.19 is lower than its current ratio, indicating that it may struggle to meet its short-term obligations if it's unable to quickly convert some of its assets into cash.

Rocket Lab's Debt / Equity ratio of 0.72 suggests that the company has a relatively high level of debt compared to its equity. This could be a concern for investors, as high debt levels can increase the risk of default.

Here's a summary of Rocket Lab's key solvency ratios:

Rocket Lab's strong backlog and defense diversification are significant factors contributing to its financial health. The company has a robust backlog of $1.067 billion as of Q1 2025, driven by government contracts like the $5.6 billion U.S. National Security Space Launch (NSSL) Phase 3 program.

This pivot into defense and high-tech sectors has accounted for ~60% of its Space Systems revenue, indicating a strategic shift towards more lucrative and stable contracts. The company's Q1 results reinforced this trajectory, with revenue rising 32% year-over-year to $122.6 million.

The upcoming Neutron rocket, a medium-lift vehicle capable of carrying 13,000 kg to LEO, adds to the optimism. Set for a late-2025 debut, Neutron could unlock lucrative contracts from NASA and commercial constellation operators, competing with SpaceX's Falcon 9.

Rocket Lab's financial position also suggests a stable foundation for its defense diversification efforts. The company has a current ratio of 2.67 and a debt/equity ratio of 0.72, indicating a manageable level of debt and sufficient liquidity to meet its obligations.

Here are some key financial metrics that support Rocket Lab's strong backlog and defense diversification:

Overall, Rocket Lab's strong backlog and defense diversification efforts are well-supported by its financial position and recent results, indicating a promising trajectory for the company's financial health.

Rocket Lab's financial health is a concern, with a return on equity (ROE) of -40.45% and return on invested capital (ROIC) of -13.13%. This indicates that the company is struggling to generate profits from its investments.

The company's revenue per employee is $240,125, but its profits per employee are -$110,150, highlighting a significant issue with profitability. With an employee count of 2,100, this means the company is losing a substantial amount of money per employee.

The asset turnover ratio of 0.37 suggests that Rocket Lab is not efficiently using its assets to generate revenue. This is a red flag for investors, as it could indicate a lack of scalability and growth potential.

Here's a breakdown of Rocket Lab's key financial metrics:

These numbers suggest that Rocket Lab is facing significant financial challenges, and investors should approach the company with caution.

Rocket Lab's stock price has increased by a staggering 436.66% in the last 52 weeks, which is a clear indication of its rapid growth. This is significantly higher than the market average, with a beta of 2.18 indicating higher price volatility.

The average 1-year price target for RKLB is 46.62 USD, with a low forecast of 20.2 USD and a high forecast of 63 USD. This suggests that analysts have a relatively broad range of expectations for the stock's future performance.

Here's a breakdown of Rocket Lab's current and non-current assets and liabilities:

The company's current liabilities total 376.5m, with accounts payable and accrued liabilities making up a significant portion of this amount.

Rocket Lab's stock price has seen a significant increase of +436.66% in the last 52 weeks, which is higher than the market average. This is a remarkable growth, especially considering the stock's beta of 2.18, indicating higher price volatility.

The stock's price movement can be gauged by its 50-Day and 200-Day Moving Averages, which stand at 46.41 and 30.81 respectively. The Relative Strength Index (RSI) is at 47.88, indicating a relatively stable market.

Here's a snapshot of Rocket Lab's stock price statistics:

The stock's price volatility is a crucial factor to consider for investors.

Short selling can be a complex topic, but let's break it down. The latest short interest is 60.31 million shares.

This number is significant because it represents 12.46% of the outstanding shares that have been sold short. That's a substantial portion of the total shares available.

To put this into perspective, the previous month saw 59.56 million shares sold short. This shows a slight increase in short selling activity.

Here's a breakdown of the short selling information:

The short ratio, which is 2.83, indicates that it would take approximately 2.83 days for all the short sellers to cover their positions. This is a relatively short period of time, which can be a sign of increased market activity.

Related reading: Rklb Short Interest

When evaluating the stock RKL, it's essential to consider the brokerage recommendations. As of today, a total of 15 brokers have made recommendations on the stock, with 8 of them strongly recommending a buy.

The strong buy recommendations are consistent, with 8 brokers suggesting a strong buy over the past three months. This suggests a high level of confidence in the stock's potential.

The ABR (Average Broker Rating) has been relatively stable, ranging from 1.87 to 1.94 over the past two months. This indicates a moderate level of enthusiasm among brokers.

Here's a breakdown of the brokerage recommendations over the past few months:

Brokerage recommendations can be a valuable tool in making informed investment decisions. The number of strong buy recommendations has remained consistent over the past few months, with 8 recommendations today, 1 week ago, and 3 months ago.

The current average brokerage recommendation (ABR) is 1.87, indicating a strong buy rating. This is based on the actual recommendations made by 15 brokerage firms.

Here's a breakdown of the current brokerage recommendations:

The number of brokers listed above is less than the number of brokerage firms that have a recommendation on the stock, which is not uncommon. This is because some firms prohibit Zacks from displaying detailed information on their recommendations.

Rocket Lab's ESA contract positions it as a leader in smallsat launches and defense tech, which could justify its premium valuation.

A successful Neutron launch could be a major catalyst for growth and further solidify Rocket Lab's position in the market.

The stock's 16.77x P/S ratio is a significant multiple, but it's not entirely unsustainable as long as revenue growth continues to accelerate.

Rocket Lab's momentum in the smallsat launches and defense tech space could help drive revenue growth and justify its premium valuation.

A clear path to profitability is crucial for Rocket Lab to sustain its valuation, but its success in Neutron launches and government contracts could make that happen.